Lundbeck has shipped Selincro (nalmefene) in its first markets and made the product available for alcohol dependent patients with high-risk drinking levels (>60g/day for men, >40g/day for women) in Norway, Finland, Poland and the Baltic countries. The launch marks the first introduction of a new treatment of alcohol dependence in Europe for more than a decade. Additional launches in other countries will follow later in 2013 and 2014.
Selincro is the first and only medicine approved for the reduction of alcohol consumption in patients with alcohol dependence. In clinical trials, Selincro reduced alcohol consumption by approximately 60 per cent after six months treatment.